PHC Holdings Valuation Multiples

PHC Holdings is valued at $1.3B as of October 2026, a 1.1x revenue multiple. In the last 12 months, PHC Holdings revenue was $2.3B and PHC Holdings EBITDA was $361M.

PHC Holdings Overview

About PHC Holdings

PHC Holdings Corp is engaged in the development, manufacture and sale of healthcare devices and services. operations are organized into three business domains: the "Diabetes Management Domain," which develops, manufactures, and sells blood glucose monitoring (BGM) systems; the "Healthcare Solutions Domain," which provides clinical testing services, develops and sells medical IT products (such as medical billing computers, electronic medical record systems, and electronic medication history systems), and offers drug discovery support services (such as contract non-clinical studies, bioanalysis, and central laboratory services); and the "Diagnostics & Life Sciences Domain," which develops, manufactures, and sells life science research and medical support equipment.


Founded

2013

HQ

Japan

Employees

10.8K

Website

phchd.com

Financials (LTM)

Revenue: $2.3B
EBITDA: $361M

EV

$2.5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PHC Holdings Financials

PHC Holdings reported last 12-month revenue of $2.3B and EBITDA of $361M.

In the same LTM period, PHC Holdings generated $1.1B in gross profit, $361M in EBITDA, and $68M in net income.

Revenue (LTM)


PHC Holdings P&L

In the most recent fiscal year, PHC Holdings reported revenue of $2.3B and EBITDA of $315M.

PHC Holdings is profitable as of last fiscal year, with gross margin of 45%, EBITDA margin of 14%, and net margin of 0%.

See analyst estimates for PHC Holdings
LTMLast FY202320242025202620272028
Revenue$2.3B$2.3B$2.2B$2.3B$2.3B
Gross Profit$1.1B$1B$1B$1B$1B
Gross Margin47%45%45%46%46%
EBITDA$361M$315M$220M$292M$318M
EBITDA Margin15%14%10%13%14%
EBIT Margin8%6%2%5%6%
Net Profit$68M$3M($66M)$29M$19M
Net Margin3%0%(3%)1%1%
Net Debt-$1.2B---

Financial data powered by Morningstar, Inc.

PHC Holdings Stock Performance

PHC Holdings has current market cap of $1.3B, and enterprise value of $2.5B.

Market Cap Evolution


PHC Holdings' stock price is $10.15.

PHC Holdings share price increased by 11.6% in the last 30 days, and by 54.9% in the last year.

PHC Holdings has an EPS (earnings per share) of $0.02.

See more trading valuation data for PHC Holdings
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2.5B$1.3B0.0%11.6%46.0%54.9%$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PHC Holdings Valuation Multiples

PHC Holdings trades at 1.1x EV/Revenue multiple, and 6.9x EV/EBITDA.

See NTM and 2027E valuation multiples for PHC Holdings

EV / Revenue (LTM)


PHC Holdings Financial Valuation Multiples

As of October 5, 2026, PHC Holdings has market cap of $1.3B and EV of $2.5B.

PHC Holdings has a P/E ratio of 18.9x.

LTMLast FY202320242025202620272028
EV/Revenue1.1x1.1x1.1x1.1x1.1x
EV/EBITDA6.9x7.9x11.3x8.5x7.8x
EV/EBIT13.8x17.3x61.4x22.4x17.4x
EV/Gross Profit2.3x2.4x2.5x2.4x2.4x
P/E18.9xn/m(19.5x)44.1x68.4x
EV/FCF11.0x11.7x17.6x13.4x12.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PHC Holdings Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PHC Holdings Margins & Growth Rates

PHC Holdings grew revenue by 3% and EBITDA by 24% in the last fiscal year.

In the most recent fiscal year, PHC Holdings reported gross margin of 45%, EBITDA margin of 14%, and net margin of 0%.

See estimated margins and future growth rates for PHC Holdings

PHC Holdings Margins

Last FY202420252026202720282029
Gross Margin45%46%46%47%
EBITDA Margin14%13%14%16%
EBIT Margin6%5%6%8%
Net Margin0%1%1%4%
FCF Margin9%8%9%10%

PHC Holdings Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%1%1%3%
Gross Profit Growth8%2%1%7%
EBITDA Growth24%33%9%17%
EBIT Growth49%174%29%37%
Net Profit Growth4033%(144%)(36%)419%
FCF Growth11%31%11%11%

Data powered by FactSet, Inc. and Morningstar, Inc.

PHC Holdings Operational KPIs

PHC Holdings' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

PHC Holdings' Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PHC Holdings' Rule of X is 24% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PHC Holdings
LTMLast FY202320242025202620272028
Rule of 4018%19%---
Bessemer Rule of X21%24%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue-39%42%40%40%
Opex to Revenue-39%44%41%39%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

PHC Holdings Competitors

PHC Holdings competitors include Weigao Group, U.S. Physical Therapy, SEEGENE, Vitrolife, SonoScape, Medartis, Sinocare, VCANBIO, Arcs Co and Alpha Tau Medical.

Most PHC Holdings public comparables operate across Healthcare Software, Medical Devices, B2B SaaS, DeepTech, HealthTech and Vertical SaaS.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Weigao Group$227M$56M4.8x4.6x19.4x14.0x
U.S. Physical Therapy$781M$110M2.5x2.3x17.6x18.9x
SEEGENE$350M$87M2.6x2.3x10.5x8.5x
Vitrolife$343M($439M)3.8x3.7x(3.0x)11.8x
SonoScape$345M$35M3.2x2.9x31.7x25.4x
Medartis$324M$53M4.5x3.7x27.1x20.7x
Sinocare$695M$43M2.0x1.9x32.4x15.7x
VCANBIO$217M$44M5.1x4.7x24.9x27.5x

This data is available for Pro users. Sign up to see all PHC Holdings competitors and their valuation data.

Start Free Trial

PHC Holdings VC Funding History

Before going public, PHC Holdings raised $184M in total equity funding, across 2 rounds.

Last private valuation of PHC Holdings was $479M, after raising a round in November 2016 from Mitsui & Co.


PHC Holdings Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-21Undisclosed stageKKR; L Catterton; Life Science Institute; Mitsui & Co; Panasonic$184M-PHC Holdings Corporation, a Tokyo-based global diversified healthcare company focused on medical devices and health data businesses, announced on March 31, 2021, a JPY 20 billion (approximately $181 million or $184 million) investment from L Catterton, joining existing shareholders KKR, Mitsui & Co., Ltd., Life Science Institute (a Mitsubishi Chemical Holdings Group member), and Panasonic Corporation. This private equity round strengthens PHC's shareholder base with L Catterton's expertise in consumer healthcare, including investments in companies like FYI Doctors, ClearChoice, 98Point6, and Patient Point, to support growth in medical devices and health data sectors. The investment aims to leverage L Catterton's network, industry knowledge, and operational excellence for strategic expansion and value creation. PHC Holdings, previously backed by major Japanese conglomerates, positions itself to capture new opportunities in healthcare with the added support from L Catterton, the largest global consumer-focused private equity firm managing approximately $25 billion in equity capital across 17 offices.
Nov-16SecondaryMitsui & Co-$479MMitsui and KKR announced a definitive share purchase agreement on November 18, 2016 under which Mitsui would acquire a 22% stake in Panasonic Healthcare Holdings from KKR. Mitsui agreed to pay JPY54.1 billion for the shares. Following completion, KKR would retain approximately 58%, Mitsui would hold approximately 22%, and Panasonic would retain approximately 20%. The purchase was a partial secondary exit for KKR, which had originally invested through its Asian Fund II. It was not a JPY54.1 billion primary capital raise by the healthcare company. Mitsui planned to use its healthcare relationships and international customer network to support the group’s expansion and the distribution of its medical devices. The target’s operations included blood glucose monitoring systems and laboratory equipment, and it had acquired Bayer’s diabetes care business earlier in 2016. The recorded consideration relates to the 22% share package; no whole-business enterprise valuation is inferred from that price.

Acquisitions by PHC Holdings

PHC Holdings has acquired 8 companies to date.

Last acquisition by PHC Holdings was on June 15th 2023. PHC Holdings acquired Scimed Life Sciences for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by PHC Holdings

Scimed Life Sciences
FUJIFILM Healthcare Systems electronic medical record and medical-receipt systems business
Xirapha Karte cloud-based EMR business
Amelieff
Description
SciMed Life Sciences is a Singapore-headquartered distributor of laboratory instruments for clinical diagnostics, biotechnology, and agriculture. The company supplies PCR systems, centrifuges, and microscopy equipment from brands like Analytik Jena across Southeast Asia.
The electronic medical record and medical-receipt systems business of FUJIFILM Healthcare Systems develops and supplies healthcare information technology for clinics in Japan. Its activities include development, sales and maintenance of electronic medical record systems and medical receipt computers. The product range also includes receipt verification software and electronic medication record systems used in clinical administration. These applications help healthcare providers organize patient information, manage reimbursement documentation and support routine operational workflows. The business was separated for acquisition by PHC Group’s Wemex subsidiary under a stock purchase agreement announced in 2023. The transferred operation is distinct from the remainder of FUJIFILM Healthcare Systems and from the broader FUJIFILM group.
The Xirapha Karte cloud-based electronic medical record business supplies software used by clinics in Japan to maintain patient records and support clinical administration. Its system links to the Standard Japan Medical Receipt Software associated with the Japan Medical Association’s ORCA organization. Launched in Japan in 2016, the service developed a customer base among clinics seeking an alternative to locally installed medical software. Its cloud architecture was intended to reduce maintenance work and support convenient access during patient visits. The business was developed by Xirapha Karte System and transferred to PHC under an agreement announced in 2021. The transferred software operation is distinct from the seller’s continuing corporate activities.
Amelieff is a Tokyo-based provider of bioinformatics services and software for life sciences research. It delivers customized genome analysis pipelines using tools like Galaxy and Bioconductor on cloud servers. Amelieff trains researchers in NGS data processing and variant calling at client sites across Japan. The company supports projects on human, plant, and microbial genomes. Founded in 2009, it serves universities and pharma firms like Takeda.
HQ CountrySingaporeJapanJapanJapan
HQ City
Singapore
-
-
Tokyo
Deal Date15 Jun 202331 Mar 202322 Feb 202130 Sep 2020
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all PHC Holdings acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by PHC Holdings

PHC Holdings has invested in 3 companies to date.

Latest investment by PHC Holdings was on March 23rd 2023. PHC Holdings invested in Lunaphore in their $32M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by PHC Holdings

Lunaphore
Lunaphore
Aiforia
Lunaphore
Description
Lunaphore Technologies is a Lausanne-headquartered spatial biology company founded in 2014. The firm develops the COMET platform, an automated system using microfluidic chips for multiplex immunofluorescence and in situ hybridization assays. Solutions enable simultaneous detection of over 40 biomarkers in tissue samples at subcellular resolution for immuno-oncology and translational research.
Lunaphore Technologies is a Lausanne-headquartered spatial biology company founded in 2014. The firm develops the COMET platform, an automated system using microfluidic chips for multiplex immunofluorescence and in situ hybridization assays. Solutions enable simultaneous detection of over 40 biomarkers in tissue samples at subcellular resolution for immuno-oncology and translational research.
Aiforia Technologies PLC equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services plan to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more.
Lunaphore Technologies is a Lausanne-headquartered spatial biology company founded in 2014. The firm develops the COMET platform, an automated system using microfluidic chips for multiplex immunofluorescence and in situ hybridization assays. Solutions enable simultaneous detection of over 40 biomarkers in tissue samples at subcellular resolution for immuno-oncology and translational research.
HQ CountrySwitzerlandSwitzerlandFinlandSwitzerland
HQ City
Lausanne
Lausanne
Helsinki
Lausanne
Deal Date23 Mar 20231 Aug 20218 Jun 20216 Feb 2020
RoundSeries DSeries ASeries BSeries C
Raised$32M$12M$15M$24M
Investorsredalpine; OCCIDENT; Ernst Gohner Stiftung; PHC Holdings; Swiss Entrepreneurs FundAlpana Ventures; OCCIDENT; PHC HoldingsPHC HoldingsAlpana Ventures; redalpine; OCCIDENT; PHC Holdings
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all PHC Holdings investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PHC Holdings

When was PHC Holdings founded?PHC Holdings was founded in 2013.
Where is PHC Holdings headquartered?PHC Holdings is headquartered in Japan.
How many employees does PHC Holdings have?As of today, PHC Holdings has over 10K employees.
Who is the CEO of PHC Holdings?PHC Holdings' CEO is Kyoko Deguchi.
Is PHC Holdings publicly listed?Yes, PHC Holdings is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of PHC Holdings?PHC Holdings trades under 6523 ticker.
When did PHC Holdings go public?PHC Holdings went public in 2021.
Who are competitors of PHC Holdings?PHC Holdings main competitors include Weigao Group, U.S. Physical Therapy, SEEGENE, Vitrolife, SonoScape, Medartis, Sinocare, VCANBIO, Arcs Co, Alpha Tau Medical.
What is the current market cap of PHC Holdings?PHC Holdings' current market cap is $1.3B.
What is the current revenue of PHC Holdings?PHC Holdings' last 12 months revenue is $2.3B.
What is the current revenue growth of PHC Holdings?PHC Holdings revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of PHC Holdings?Current revenue multiple of PHC Holdings is 1.1x.
What is the current EBITDA of PHC Holdings?PHC Holdings' last 12 months EBITDA is $361M.
What is PHC Holdings' EBITDA margin?PHC Holdings' last 12 months EBITDA margin is 15%.
What is the current EV/EBITDA multiple of PHC Holdings?Current EBITDA multiple of PHC Holdings is 6.9x.
What is the current FCF of PHC Holdings?PHC Holdings' last 12 months FCF is $225M.
What is PHC Holdings' FCF margin?PHC Holdings' last 12 months FCF margin is 10%.
What is the current EV/FCF multiple of PHC Holdings?Current FCF multiple of PHC Holdings is 11.0x.
How many companies PHC Holdings has acquired to date?As of October 2026, PHC Holdings has acquired 7 companies.
What was the largest acquisition by PHC Holdings?$1.1B acquisition of Epredia on 29th January 2019 was the largest M&A PHC Holdings has done to date.
In how many companies PHC Holdings has invested to date?As of October 2026, PHC Holdings has invested in 3 companies.
What was the last PHC Holdings investment?On 23rd March 2023 PHC Holdings invested in Lunaphore, participating in a $32M Series D round, alongside redalpine, OCCIDENT, Ernst Gohner Stiftung, and Swiss Entrepreneurs Fund.
In what companies PHC Holdings invested in?PHC Holdings invested in Lunaphore, Aiforia, and KAKEHASHI.

See public comps similar to PHC Holdings

Lists including PHC Holdings

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial